Opiant Pharmaceuticals – Consensus Indicates Potential 414.1% Upside

Broker Ratings

Opiant Pharmaceuticals found using ticker (OPNT) now have 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 44 and 38 with a mean TP of 41.33. With the stocks previous close at 8.04 this is indicating there is a potential upside of 414.1%. The 50 day moving average now sits at 8.08 and the 200 day moving average is 8.45. The company has a market cap of $34m. You can visit the company’s website by visiting: http://www.opiant.com

Opiant Pharmaceuticals, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals in January 2016. Opiant Pharmaceuticals was founded in 2005 and is headquartered in Santa Monica, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index